📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º ensayo en humanos de aumento de dosis, de etiqueta abierta, no aleatorizado. https://t.co/UAHyZArWbC Original: https://t.co/tnYUPSzM0r
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @DOCTORMARIOFM: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/f8ZpMu7Igd https://t.co/dsyi2mSLyO
@Vitalityyyyyy @PinotNwar @Conflits_FR il y a le résultat de la phase I qui a été publié, par rapport à la Phase II, je n'ai pas trop suivi les infos. https://t.co/J7n2HA9PTN
RT @doritmi: Promising prepiminary results of another #COVID19 vaccine trial, though only stage I. https://t.co/vlRC4lv6Oh #vaccines #vacci…
RT @doritmi: Promising prepiminary results of another #COVID19 vaccine trial, though only stage I. https://t.co/vlRC4lv6Oh #vaccines #vacci…
RT @YanzhongHuang: These are two inactivated vaccines developed by CNBG (Sinopharm), which are different from the adenovirus vaccine develo…
RT @YanzhongHuang: These are two inactivated vaccines developed by CNBG (Sinopharm), which are different from the adenovirus vaccine develo…
These are two inactivated vaccines developed by CNBG (Sinopharm), which are different from the adenovirus vaccine developed by Beijing Institute of Biotechnology (led by general Chen Wei), another forerunner in the global race of vaccine development. https
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/krQ3TYt2UA
RT @bhkiesel: Positive news. The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able…
@jeuasommenulle You are totally spot on, it's very disappointing. If you add the fact that it seems challenging for a lot of people to read past the headlines, you have the recipe for a lot of misinformation (eg. https://t.co/39EWlTyhtr)
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @SEMERGENap: 📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º e…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/AXx9GbhzRJ
RT @SEMERGENap: 📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @strategieduchoc: Un jour après avoir averti de la dangerosité la #HydroxyChloroquine @TheLancet nous prendrait-il pour des cons en pub…
RT @doritmi: Promising prepiminary results of another #COVID19 vaccine trial, though only stage I. https://t.co/vlRC4lv6Oh #vaccines #vacci…
RT @SEMERGENap: 📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º e…
📙Seguridad, tolerabilidad e inmunogenicidad de una #vacuna #COVID19 vectorizada por adenovirus tipo 5 recombinante: el 1º ensayo en humanos de aumento de dosis, de etiqueta abierta, no aleatorizado. https://t.co/UAHyZArWbC Original: https://t.co/tnYUPSzM0r
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Promising prepiminary results of another #COVID19 vaccine trial, though only stage I. https://t.co/vlRC4lv6Oh #vaccines #vaccineswork #coronavirus
A phase 1 trial of a corona vaccine candidate. /// Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/HbIcpc22oo
RT @acinnacional: Actualmente se realiza seguimiento a largo plazo de los voluntarios y se está realizando un estudio fase II. https://t.co…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/zPSWD7BpXm
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @ChinaEmbEsp: El estudio de la primera vacuna #china contra el #COVID19 que ha alcanzado el ensayo clínico de fase 1 ha demostrado ser s…
RT @paulcarald: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, o…
RT @paulcarald: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, o…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/jMMhGOq2Qp
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @CrisBonorino: First human trial of a #COVID19 vaccine
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @Dr_Nck: Otro pasito
Otro pasito
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/5CVO7r6gyD
RT @CrisBonorino: First human trial of a #COVID19 vaccine
Seguridad, tolerancia e inmunogenicidad de #vacuna recombinante para #COVID__19: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/oHq4JNfzbA
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
@RIYADH1820 @mnt خبر ماهو جديد ... يطول عمر https://t.co/oZJoAhQm0I
RT @CrisBonorino: First human trial of a #COVID19 vaccine
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @AmbChenWeiQing: نشرت مجلة #The_Lancet نتائج المرحلة الأولى من #التجارب_السريرية لأول لقاح ناقل #فيروس_الغدي_المؤتلف ضد #كوفيد_19 في ال…
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @mariofitzm: Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Primer ensayo de vacuna anti coronavirus en HUMANOS. Falta pero hay buenos resultados!
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/eW8z8u4nLZ
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine. https://t.co/VbbtUvlhKg
RT @dylanbgeorge: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine https://t.co/qODuXU…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/hhycsdTtV2
1st #COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated & able to generate immune response against SARS-CoV-2 in humans. https://t.co/X1loDkWw2g @TheLancet
RT @CrisBonorino: First human trial of a #COVID19 vaccine
RT @AUBMCED: Many different vaccines, with a variety of pros and cons are in rapid development.This first-in-human trial of Ad5 vectored CO…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Feeling speechless.... Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial https://t.co/yqf1Pr1MWg
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://t.co/oZMrAWpUQ8
RT @MonsieurQFB: Buenas noticias, los resultados de fase 1 de la vacuna China ya fue revisada por pares científicos y da alentadores result…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine https://t.co/qODuXUQWTB
RT @MonsieurQFB: Buenas noticias, los resultados de fase 1 de la vacuna China ya fue revisada por pares científicos y da alentadores result…
Positive news. The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans. https://t.co/yfLINB6ygZ
China, has a Vaccine for Coronavirus.. Because it was "made in China".., the US will stubbornly refuse to administer it to it's now, at 105,000 deaths population.. Kudos to Chinese Scientists and Co-workers on the quick, proven Vaccine.. https://t.co/19VSH
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial > from @TheLancet https://t.co/YBZJH6KWah
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
RT @TheLancet: NEW Research—First human trial of #COVID19 vaccine finds it is safe and induces rapid immune response: finding from a dose-e…
Investigación acerca de los ensayos en humanos de la vacuna contra el #SARSCov2 por parte de médicos chinos. 👇🏻